Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07779018 tanCART-19/22 cells(Chinese PLA General Hospital) High grade B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07779018 tanCART-19/22 cells(Chinese PLA General Hospital) High grade B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07779018 clinical trial report covering tanCART-19/22 cells(Chinese PLA General Hospital), Phase 2, endpoints, sponsor, geography, readout timing and de
Read →
ChiCTR2600130553 Albumin-Bound Paclitaxel Unresectable Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600130553 Albumin-Bound Paclitaxel Unresectable Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600130553 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07777380 Cycloserine Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07777380 Cycloserine Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07777380 clinical trial report covering Cycloserine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600130583 Anlotinib Dihydrochloride Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600130583 Anlotinib Dihydrochloride Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600130583 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spa
Read →
NCT07778810 Cannabidiol Sturge-Weber Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07778810 Cannabidiol Sturge-Weber Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07778810 clinical trial report covering Cannabidiol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07779616 PTC-844 Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07779616 PTC-844 Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07779616 clinical trial report covering PTC-844, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07778745 Trastuzumab Rezetecan Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07778745 Trastuzumab Rezetecan Non-small cell lung cancer stage III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07778745 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07779811 Metformin Hydrochloride Melanosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07779811 Metformin Hydrochloride Melanosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07779811 clinical trial report covering Metformin Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600130597 Adebrelimab Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600130597 Adebrelimab Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600130597 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07780721 Adebrelimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07780721 Adebrelimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07780721 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07778368 Toripalimab Squamous cell carcinoma of the oral cavity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07778368 Toripalimab Squamous cell carcinoma of the oral cavity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07778368 clinical trial report covering Toripalimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07779694 Serplulimab pMMR/​MSS/MSI-L Colon Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07779694 Serplulimab pMMR/​MSS/MSI-L Colon Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07779694 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →